Firebrick Pharmas Phase 3 Trial of Nasodine Resumes
Filed with ASX · · 3 pages · English
Firebrick Pharma Limited (ASX: FRE) (the Company or Firebrick) is pleased to announce that its Phase 3 clinical trial of Nasodine Nasal Spray (“Nasodine”) as a treatment for the common cold has received the necessary ethics approvals to re-open for the 2023 common cold season. Two clinical sites in Australia are now open for recruitment and three sites in South Africa will be open in the next week
Firebrick Pharma Limited on 6ix
Story so far
Earlier from Firebrick Pharma
- FRE files EU Paediatric Investigation Plan for Nasodine
- Appendix 4D & Half Yearly Report and Accounts
- December 2022 Quarterly Activity Report & Appendix 4C
- Nasodine Composition Patent Accepted in Australia
- Firebrick Receives $1.08m R&D Tax Incentive
Later from Firebrick Pharma
- Nasodine COVID-19 Trial Concludes Recruitment
- March 2023 Quarterly Activity Report & Appendix 4C
- Firebrick Raises $1 million via Placement
- Nasodine Phase 3 Clinical Trial Surpasses 80% Recruitment
- June 2023 Quarterly Activity Report & Appendix 4C
Follow Firebrick Pharma into a list and get an email when it puts out news.
Follow Firebrick Pharma